STXS Quote, Financials, Valuation and Earnings

Electromed has a net margin of -77.93% compared to Stereotaxis's net margin of 12.06%. Stereotaxis's return on equity of -174.6% beat Electromed's return on equity of 16.57%.

Stereotaxis has a consensus price target of $4.50, signalling upside risk potential of 88.29%. On the other hand Electromed has an analysts' consensus of $33.50 which suggests that it could grow by 81.87%. Given that Stereotaxis has higher upside potential than Electromed, analysts believe Stereotaxis is more attractive than Electromed.

Stereotaxis has a beta of 1.440, which suggesting that the stock is 43.964% more volatile than S&P 500. In comparison Electromed has a beta of 0.413, suggesting its less volatile than the S&P 500 by 58.696%.

Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Electromed offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. Electromed pays out -- of its earnings as a dividend.

Stereotaxis quarterly revenues are $7.5M, which are smaller than Electromed quarterly revenues of $15.7M. Stereotaxis's net income of -$5.8M is lower than Electromed's net income of $1.9M. Notably, Stereotaxis's price-to-earnings ratio is -- while Electromed's PE ratio is 23.32x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 7.49x versus 2.69x for Electromed. Usually stocks with elevated PS ratios are considered overvalued.

IRIDEX has a net margin of -77.93% compared to Stereotaxis's net margin of -14.17%. Stereotaxis's return on equity of -174.6% beat IRIDEX's return on equity of -218.69%.

Stereotaxis has a consensus price target of $4.50, signalling upside risk potential of 88.29%. On the other hand IRIDEX has an analysts' consensus of -- which suggests that it could grow by 86.92%. Given that Stereotaxis has higher upside potential than IRIDEX, analysts believe Stereotaxis is more attractive than IRIDEX.

Stereotaxis has a beta of 1.440, which suggesting that the stock is 43.964% more volatile than S&P 500. In comparison IRIDEX has a beta of 0.566, suggesting its less volatile than the S&P 500 by 43.407%.

Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IRIDEX offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. IRIDEX pays out -- of its earnings as a dividend.

Stereotaxis quarterly revenues are $7.5M, which are smaller than IRIDEX quarterly revenues of $11.9M. Stereotaxis's net income of -$5.8M is lower than IRIDEX's net income of -$1.7M. Notably, Stereotaxis's price-to-earnings ratio is -- while IRIDEX's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 7.49x versus 0.36x for IRIDEX. Usually stocks with elevated PS ratios are considered overvalued.

Modular Medical has a net margin of -77.93% compared to Stereotaxis's net margin of --. Stereotaxis's return on equity of -174.6% beat Modular Medical's return on equity of --.

Stereotaxis has a consensus price target of $4.50, signalling upside risk potential of 88.29%. On the other hand Modular Medical has an analysts' consensus of $8.00 which suggests that it could grow by 1034.59%. Given that Modular Medical has higher upside potential than Stereotaxis, analysts believe Modular Medical is more attractive than Stereotaxis.

Stereotaxis has a beta of 1.440, which suggesting that the stock is 43.964% more volatile than S&P 500. In comparison Modular Medical has a beta of -4.943, suggesting its less volatile than the S&P 500 by 594.256%.

Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Modular Medical offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. Modular Medical pays out -- of its earnings as a dividend.

Stereotaxis quarterly revenues are $7.5M, which are larger than Modular Medical quarterly revenues of --. Stereotaxis's net income of -$5.8M is lower than Modular Medical's net income of -$4.9M. Notably, Stereotaxis's price-to-earnings ratio is -- while Modular Medical's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 7.49x versus -- for Modular Medical. Usually stocks with elevated PS ratios are considered overvalued.

Myomo has a net margin of -77.93% compared to Stereotaxis's net margin of -35.24%. Stereotaxis's return on equity of -174.6% beat Myomo's return on equity of -38.11%.

Stereotaxis has a consensus price target of $4.50, signalling upside risk potential of 88.29%. On the other hand Myomo has an analysts' consensus of $8.70 which suggests that it could grow by 346.15%. Given that Myomo has higher upside potential than Stereotaxis, analysts believe Myomo is more attractive than Stereotaxis.

Stereotaxis has a beta of 1.440, which suggesting that the stock is 43.964% more volatile than S&P 500. In comparison Myomo has a beta of 1.389, suggesting its more volatile than the S&P 500 by 38.863%.

Stereotaxis has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Myomo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Stereotaxis pays -- of its earnings as a dividend. Myomo pays out -- of its earnings as a dividend.

Stereotaxis quarterly revenues are $7.5M, which are smaller than Myomo quarterly revenues of $9.8M. Stereotaxis's net income of -$5.8M is lower than Myomo's net income of -$3.5M. Notably, Stereotaxis's price-to-earnings ratio is -- while Myomo's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Stereotaxis is 7.49x versus 1.97x for Myomo. Usually stocks with elevated PS ratios are considered overvalued.